drugset / Trial / NCT03649464
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
NaSequentialOpen-labelTreatment
Summary
The objective of this study is to investigate tolerability, safety, pharmacokinetics (PK) and efficacy of oral OKN-007 in participants with recurrent high-grade glioma.
Timeline
- Start
- 2022-08
- Primary completion
- 2025-04
- Completion
- 2025-08
Outcome
Outcome not reported
Stopped: “Planned to execute the new Oral OKN-007 clinical trial with modified study plan soon. This Study not proceeding and sites never opened.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DISUFENTON | Small molecule | 1000 mg | Oral |
| Subject | DISUFENTON | Small molecule | 1500 mg | Oral |